PRLog - Feb. 14, 2013 - ATLANTA -- The Center for the Biology of Chronic Disease (CBCD) recently learned that according to a new article on Medscape regarding neonatal herpes infection, “the American Academy of Pediatrics (AAP) has developed a new management algorithm to guide evaluation of asymptomatic neonates. The new guidelines were published online January 28 in Pediatrics.”
Gene-Eden-VIR is effective in boosting the immune system against herpes.
Every year, around 1500 out of every 4 million births are cases wherein HSV is transferred from mother to infant during birth.
The CBCD would like to point out that research shows that the risk for transmission is much lower in mothers with recurrent lesions rather than a first-time infection.
Specific recommendations from the AAP are as follows:
Women in labor with visible genital lesions should be swabbed for HSV PCR and culture. Any positive test result should be further analyzed to determine whether the virus is HSV-1 or HSV-2.
A history of genital herpes should be obtained preceding the pregnancy.
In cases of a recurrent maternal herpes outbreak, the following steps should be taken:
Skin and mucosal specimens should be obtained from the neonate for culture and PCR assay at approximately 24 hours after delivery, and blood should be sent for HSV DNA PCR assay. Preemptive treatment with the antiviral drug acyclovir need not be started as long as the infant remains asymptomatic.
If results become positive within 5 days, thus confirming neonatal HSV infection, the infant should undergo a complete evaluation to determine the extent of disease, and intravenous acyclovir should be initiated as soon as possible.
Genital herpes is one of the more common sexually transmitted diseases in the United States. The CBCD is in favor of all methods of prevention. Helping women to increase their awareness about possible exposure risks is very important.
After an initial period of activity where there can be up to 5 major outbreaks in a year, Herpes establishes what scientists call a latent infection. When a virus is latent, it acts as if it is asleep. It is dormant. The moment your immune system is weakened however, the Herpes virus can “wake up” and become active again.
The best defense against a latent herpes infection is a healthy immune system.
That’s why the CBCD would like to point out a Herpes remedy that boosts the immune system and helps target the dormant (latent) HSV virus.
“The key to your health is to reduce the level of the chronic viruses in your body to harmless levels.” – Dr. Hanan Polansky
The name of that antiviral remedy is Gene-Eden-VIR. This all-natural product was scientifically designed to help the human body maintain low concentrations of the dormant or latent herpes virus.
By helping the body’s immune system target the latent herpes virus, people also lower their risk of developing fever blisters, cold sores, or genital herpes symptoms. This is just one reason the CBCD believes Gene-Eden-VIR is an important product.
To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent herpes virus and that is scientifically backed by published material, visit http://www.gene-
The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.
The CBCD published the “Purple” book entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” written by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.
We invite biologists, virologists, and scientists everywhere to download Dr. Polansky’s book here: http://cbcd.net/